MaxCyte Inc (LON:MXCT) is well-positioned to leverage its proprietary flow electroporation technology that is driving innovation, not only for its differentiated cell therapy platform CARMA but for a fast-growing list of leading industry partners. MXCT has more than 80 licensed programmes including
26 Nov 2019
MaxCyte - Pole Position in Cell and Gene Therapy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
MaxCyte - Pole Position in Cell and Gene Therapy
MaxCyte, Inc. (MXCT:LON) | 313 0 0.0% | Mkt Cap: 325.9m
- Published:
26 Nov 2019 -
Author:
Emma Ulker -
Pages:
22
MaxCyte Inc (LON:MXCT) is well-positioned to leverage its proprietary flow electroporation technology that is driving innovation, not only for its differentiated cell therapy platform CARMA but for a fast-growing list of leading industry partners. MXCT has more than 80 licensed programmes including